- Home
- WERN vs GHRS Comparison
WERN vs GHRS Comparison
Compare WERN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | GHRS |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WERN | GHRS |
|---|---|---|
| Price | $37.55 | $28.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $33.79 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.2M | 330.5K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,974,396,000.00 | N/A |
| Revenue This Year | $22.24 | N/A |
| Revenue Next Year | $6.33 | N/A |
| P/E Ratio | $1,296.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.06 | $11.83 |
| 52 Week High | $47.49 | $31.44 |
Technical Indicators
Market Signals| Indicator | WERN | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 49.28 |
| Support Level | $35.67 | $28.05 |
| Resistance Level | $38.82 | $28.96 |
| Average True Range (ATR) | 1.24 | 1.49 |
| MACD | 0.19 | -0.27 |
| Stochastic Oscillator | 50.19 | 26.83 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.